Phenotyping the Clotting System

• References

• 1 Agnelli G. Thrombin plays a pivotal role in vascular re-occlusion after PTCA and coronary thrombolysis. Cardiovasc Res 1996; 31: 232-4.
• 2 Badimon L, Meyer BJ, Badimon JJ. Thrombin in arterial thrombosis. Haemostasis 1994; 24: 69-80.
• 3 Chesebro JH, Rauch U, Fuster V, Badimon JJ. Pathogenesis of thrombosis in coronary artery disease. Haemostasis 1997; 27: 12-8.
• 4 Fuster VVM. Thrombosis in Cardiovascular Disorders. Philadelphia: W. B. Saunders; 1992
• 5 A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980; 02: 989-94.
• 6 Neri GGSerneri, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 01: 937-42.
• 7 Kumar R, Béguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation – evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
• 8 Roy AB. Catastrophes and bifurcations in biochemical networks. In: Catastrophe, Theory and Applications. Sinha DK. ed. New York: John Wiley & sons; 1981: 112-9.
• 9 Selkov EE. Non linearity of multienzyme systems. In: Analysis and simulation of Biochemical Systems. Hemker HC, Hess B. eds. Amsterdam, North Holland: American Elsevier; 1972: 145-62.
• 10 Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-78.
• 11 Mann KG. How much factor V is enough?. Thromb Haemost 2000; 83: 3-4.
• 12 Seegers WH. A personal perspective on hemostasis and thrombosis (1937-1981). Semin Thromb Hemost 1981; 07: 177-307.
• 13 Biggs R, Macfarlane RG. Human Blood Coagulation and its Disorders. Oxford: Blackwell; 1953
• 14 Hartert HSJA. The physical and biological constants of thrombelastography. Biorheology 1962; 01: 31-9.
• 15 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
• 16 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-4.
• 17 Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorr. 1965. Suppl. 17: 35-44.
• 18 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
• 19 Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
• 20 Cawthern KM, van’t Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
• 21 Rapaport SI, Rao LV. The tissue factor pathway: how it has become a prima ballerina. Thromb Haemost 1995; 74: 7-17.
• 22 Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
• 23 Rijkers DT, Wielders SJ, Tesser GI, Hemker HC. Design and synthesis of thrombin substrates with modified kinetic parameters. Thromb Res 1995; 79: 491-9.
• 24 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
• 25 Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, Kakkar V, Hemker HC, Béguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
• 26 Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 589-91.
• 27 Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 863-74.
• 28 Duchemin J, Pittet JL, Tartary M, Béguin S, Gaussem P, Alhenc-Gelas M, Aiach M. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994; 71: 331-8.
• 29 Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
• 30 Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
• 31 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62.
• 32 Hemker HC. The mode of action of heparin in plasma. In: Thromb Haemost 1987. Verstraete MVJ, Lijnen R, Arnout J. ed. Leuven: Leuven University Press; 1987: 17-36.
• 33 Xi M, Béguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989; 62: 788-91.
• 34 Kyrle PA, Mannhalter C, Béguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
• 35 Rotteveel RC, Roozendaal KJ, Eijsman L, Hemker HC. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993; 70: 959-62.
• 36 Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177: 887-91.
• 37 Azar AJ, Cannegieter SC, Deckers JW, Briët E, van Bergen PF, Jonker JJ, Rosendaal FR. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996; 27: 1349-55.
• 38 Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma – a study in human volunteers. Thromb Haemost 1994; 72: 705-12.
• 39 Keularts IMLW, Zivellin A, Seligsohn U, Hemker HC, Béguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost. 2000 submitted.
• 40 Béguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-70.
• 41 Herault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost 1999; 81: 957-60.
• 42 Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood – the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
• 43 Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 1999; 81: 400-6.
• 44 Ramjee MK. The Use of Fluorogenic Substrates to Monitor Thrombin Generation for the Analysis of Plasma and Whole Blood Coagulation. Anal Biochem 2000; 277: 11-8.
• 45 Bos GM, Rijkers DT, Willems HP, den Heijer M, Béguin S, Gerrits WB, Hemker HC. The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential. Thromb Haemost 1999; 81: 467-8.